Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes
Authors' conclusion
Tirzepatide significantly improves insulin sensitivity within 12 weeks, indicating an early metabolic effect that is not solely attributable to weight loss.
Study context
- Population
- Japanese individuals with obesity and T2D16 completed
- Outcome
- Change in glucose infusion rate (GIR) on hyperinsulinaemic-euglycaemic clamp
- Follow-up
- 12 weeks
Methodological detailsopen-label, single-centre
- Open-label
- Single-centre
Main finding
As reported in the abstract
GIR
Glucose infusion rate (GIR) increased from baseline (mg min-1 kg-1), p<0.001
3.21 to 5.16
Observational data: associations, not effects.
Secondary outcomes
HbA1c · 12 weeks
- HbA1c decreased (mmol/mol), p<0.001
- 63.4 to 43.6
- HbA1c decreased (%), p<0.001
- 7.95% to 6.14%
Body weight · 12 weeks
- Body weight decrease, p<0.001
- 4.9 kg (5.0%)
Body composition · 12 weeks
- Muscle mass significantly decreased
- 1.8%
- Fat mass significantly decreased
- 9.1%
- Fat percentage significantly decreased
- 4.5%
Glucagon · 12 weeks
- Glucagon decreased significantly
- 28.8 pg/ml to 20.8 pg/ml
Association of GIR change with other variables
- No significant relationship between changes in GIR and other clinical variables (simple linear regression)
Original publication
Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes. Diabetologia. Published 22 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →